Initial Efficacy of Anti-Lymphocyte Activation Gene-3 (anti–LAG-3; BMS-986016) in Combination With Nivolumab in Patients With Melanoma Previously Treated With Anti–PD-1/PD-L1 Therapy

Paola Antonio Acencio,1,2 Ignacio Melero,3 Shailender Bratda,4,5 Potri Bonifazi,6 Raphael E. Sabioni,6 Exa J. Lipsone,6 Margaret K. Caldwell,6 Thomas Gaugkoni,6 Carlos A. Gomez-Rossi,6 Stephen Holl,6 Oksana Czitlag,1,2 Marta Mykyta,7,8 Matthias Presosos,9 Yevheniia Kropeli,9 Matteo Mavera,9 Raphael Gyose,10 Piirim Mita,10 Suryendro Suryawanshi,10 Alan Kerman,10 Eva Mulico-Cousins10

1Division of Natural Sciences, Faculty of Medicine, University of Navarra, Pamplona, Spain. 2Department of Molecular Biology and Immunology, Centro de Investigación Biomédica en Red de Oncología, Madrid, Spain. 3Translational Immunology and Signals Laboratory, Department of Pathology, Dana-Farber Cancer Institute, Boston, MA. 4Department of Medical Oncology, University of Manchester, Manchester, UK. 5Division of Cancer Epidemiology and Prevention, Dana-Farber Cancer Institute, Boston, MA. 6Department of Medical Oncology, University of Manchester, Manchester, UK. 7Division of Hematology, Comprehensive Cancer Center, St. Mary’s, Kansas City, Missouri. 8Division of Hematology-Oncology, Comprehensive Cancer Center, Clay, Missouri. 9Division of Hematology, Medical University of Vienna, Vienna, Austria. 10Division of Blood and Marrow Transplant, Memorial Sloan Kettering Cancer Center, New York, NY.

Background

LAG-3, an immune cell receptor, regulates a checkpoint pathway that limits the activity of T cells1,2 and is highly expressed on T cells with an exhausted or memory phenotype.3 LAG-3 may interact with CD80 and CD86,4 and increase expression of LAG-3 to promote T-cell exhaustion, anti–PD-1 drug resistance IO therapy exposed:• KIR, anti–killer-cell immunoglobulin-like receptor.

Methods

Study Design

This was a single-center, open-label, non-randomized, non-placebo-controlled, dose-escalation study. The patients and families that made this study possible are thanked.

Results

Safety

• Safety


Summary and Potential Implications

Table 3. Response by Baseline Characteristics (investigator assessed).

Table 4. Summary of Grade 3/4 TRAEs per 100 Patient-Months.

References

Acknowledgments

Scientific Content De-demand

To receive a copy of the anti–LAG-3/BMS-986016 presentation, please contact your field representative.

+1 855 724 0887 or
sales@newswise.com


E-mail: paola.acencio@navarre.es

To view this presentation digitally, contact the author to receive a digital copy.


E-mail: paola.acencio@navarre.es

To view this presentation digitally, contact the author to receive a digital copy.